Related Experiment Videos
Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies
Richard E Pratley1, Thérèse McCall, Penny R Fleck
1Diabetes and Metabolism Translational Medicine Unit, Department of Medicine, College of Medicine, University of Vermont. Burlington, Vermont 05403, USA. richard.pratley@uvm.edu
Journal of the American Geriatrics Society
|October 2, 2009
Summary
Alogliptin effectively lowers blood sugar in older adults with type 2 diabetes, showing similar efficacy and safety to younger patients. This DPP-4 inhibitor is well-tolerated, with no increased risk of hypoglycemia or weight gain in the elderly.
Area of Science:
- Endocrinology
- Pharmacology
Background:
- Type 2 diabetes mellitus (T2DM) is a global health concern, particularly in aging populations.
- Glycemic control in elderly patients with T2DM presents unique challenges due to comorbidities and altered pharmacokinetics.
- Dipeptidyl peptidase-4 (DPP-4) inhibitors offer a therapeutic option for T2DM management.
Purpose of the Study:
- To evaluate the efficacy and safety of alogliptin in elderly (≥65 years) versus younger (<65 years) patients with T2DM.
- To compare glycemic control improvements and safety profiles between age groups treated with alogliptin.
Main Methods:
- Pooled analysis of six randomized, double-blind, placebo-controlled studies.
- Included patients aged 18-80 with T2DM and inadequate glycemic control.
- Compared alogliptin (12.5 mg or 25 mg) versus placebo for 26 weeks, as monotherapy or with background agents.
Main Results:
- Alogliptin significantly reduced HbA1c and fasting plasma glucose in both elderly and younger patients compared to placebo.
- Glycemic improvements were comparable between elderly and younger patient groups.
- Incidence of hypoglycemia, weight changes, and adverse events were similar across age groups and alogliptin doses.
Conclusions:
- Alogliptin demonstrates significant efficacy in improving glycemic control in elderly patients with T2DM.
- The drug is well-tolerated in older adults, with a safety profile comparable to younger patients.
- Alogliptin represents a safe and effective treatment option for glycemic management in the elderly T2DM population.
Related Concept Videos
01:22Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
01:00Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
01:15Drug Dosing: Geriatric Patients
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...